{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:13:28Z","timestamp":1792019608855,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["735-63253255"],"award-info":[{"award-number":["735-63253255"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470167"],"award-info":[{"award-number":["82470167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373134"],"award-info":[{"award-number":["82373134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["824B2114"],"award-info":[{"award-number":["824B2114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404442"],"award-info":[{"award-number":["82404442"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012326","name":"International Science and Technology Cooperation Programme","doi-asserted-by":"publisher","award":["2022YFE0133300"],"award-info":[{"award-number":["2022YFE0133300"]}],"id":[{"id":"10.13039\/501100012326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["24JCYBJC01990"],"award-info":[{"award-number":["24JCYBJC01990"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M751531"],"award-info":[{"award-number":["2024M751531"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023T029TJ"],"award-info":[{"award-number":["2023T029TJ"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118617","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:46:07Z","timestamp":1769874367000},"page":"118617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer"],"prefix":"10.1016","volume":"307","author":[{"given":"Lei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranlu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-9392","authenticated-orcid":false,"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2026.118617_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118617_bib2","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","article-title":"Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer","volume":"11","author":"Scher","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/106002809703100112","article-title":"Nilutamide: an antiandrogen for the treatment of prostate cancer","volume":"31","author":"Dole","year":"1997","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118617_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0090-4295(94)90092-2","article-title":"Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome","volume":"43","author":"Small","year":"1994","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118617_bib5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118617_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","article-title":"Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial","volume":"66","author":"Attard","year":"2014","journal-title":"Eur. Urol."},{"issue":"28","key":"10.1016\/j.ejmech.2026.118617_bib7","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118617_bib8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118617_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118617_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS290","article-title":"A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Petrylak","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4_SUPPL","key":"10.1016\/j.ejmech.2026.118617_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2024.42.4_suppl.134","article-title":"First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Rathkopf","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118617_bib12","first-page":"ND2","article-title":"GDC-2992: a heterobifunctional androgen receptor (AR) antagonist and degrader for the treatment of AR wild-type and mutant prostate cancer","volume":"85","author":"Metcalfe","year":"2025","journal-title":"Cancer Res."},{"issue":"33","key":"10.1016\/j.ejmech.2026.118617_bib13","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118617_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112512","article-title":"The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader","volume":"204","author":"Xie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118617_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.eururo.2009.06.027","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment targets","volume":"56","author":"Chi","year":"2009","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118617_bib16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118617_bib17","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"38","key":"10.1016\/j.ejmech.2026.118617_bib19","doi-asserted-by":"crossref","first-page":"26417","DOI":"10.1074\/jbc.M114.553818","article-title":"Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer","volume":"289","author":"Dalal","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118617_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118617_bib21","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1535-7163.MCT-17-0259","article-title":"Bypassing drug resistance mechanisms of prostate cancer with small molecules that target androgen receptor-chromatin interactions","volume":"16","author":"Dalal","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118617_bib22","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/ijms22052493","article-title":"Development of novel inhibitors targeting the D-Box of the DNA binding domain of androgen receptor","volume":"22","author":"Radaeva","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41401-021-00632-5","article-title":"Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays","volume":"43","author":"Pang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118617_bib24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/cb400759d","article-title":"Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium","volume":"9","author":"Lim","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/cbdd.13068","article-title":"Synthesis and evaluation of novel thiazole-based derivatives as selective inhibitors of DNA-binding domain of the androgen receptor","volume":"91","author":"Xu","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118617_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41589-022-01151-y","article-title":"Targeting androgen receptor phase separation to overcome antiandrogen resistance","volume":"18","author":"Xie","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118617_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118617_bib28","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting n-terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118617_bib29","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1021\/acs.jmedchem.5c00443","article-title":"Rational design of dual degraders by incorporating molecular glue structural features into PROTAC degraders","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118617_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117079","article-title":"Discovery of a highly potent, N-terminal domain-targeting degrader of AR-FL\/AR-V7 for the treatment of prostate cancer","volume":"282","author":"Ha","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118617_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/0008-5472.CAN-24-0591","article-title":"An autophagy-targeting chimera induces degradation of androgen receptor mutants and AR-V7 in castration-resistant prostate cancer","volume":"85","author":"Bae","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118617_bib32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acscentsci.5c00959","article-title":"DCAF16-based covalent degradative handles for the modular design of degraders","volume":"11","author":"Orr","year":"2025","journal-title":"ACS Cent. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118617_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational chemical design of molecular glue degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118617_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113376","article-title":"Identification of novel androgen receptor degrading agents to treat advanced prostate cancer","volume":"217","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118617_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118259","article-title":"Development of dual AR\/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"301","author":"Zhang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118617_bib36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ejmech.2018.08.059","article-title":"Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor","volume":"157","author":"Dalal","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118617_bib37","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-17-0976","article-title":"Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer","volume":"77","author":"Ponnusamy","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118617_bib38","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118617_bib39","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1016\/j.apsb.2022.05.003","article-title":"A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118617_bib40","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1021\/acs.jmedchem.3c02177","article-title":"Structure\u2013activity relationship (SAR) studies of novel monovalent AR\/AR-V7 dual degraders with potent efficacy against advanced prostate cancer","volume":"67","author":"Xiao","year":"2024","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118617_bib41","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1021\/acs.jmedchem.2c01487","article-title":"A comprehensive overview of small-molecule androgen receptor degraders: recent progress and future perspectives","volume":"65","author":"Ha","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118617_bib42","doi-asserted-by":"crossref","first-page":"21344","DOI":"10.1021\/acs.jmedchem.4c02273","article-title":"Development of novel silicon-based hydrophobic tags (SiHyT) for targeted proteins degradation","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118617_bib43","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118617_bib44","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1080\/07391102.2024.2333454","article-title":"In silico study of androgen receptor N-terminal domain and exploration of its modulators","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118617_bib45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbrc.2018.09.149","article-title":"BAF53A regulates androgen receptor-mediated gene expression and proliferation in LNCaP cells","volume":"505","author":"Jin","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118617_bib46","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/en.2010-0138","article-title":"3\u03b2-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer","volume":"151","author":"Evaul","year":"2010","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118617_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2009.08.151","article-title":"Biochemical characterisation of the SWI\/SNF family member HLTF","volume":"390","author":"MacKay","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-015-2060-6","article-title":"The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?","volume":"73","author":"Dhont","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118617_bib49","first-page":"2780","article-title":"HLTF suppresses the migration and invasion of colorectal cancer cells via TGF-\u03b2\/SMAD signaling in vitro","volume":"53","author":"Liu","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118617_bib50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/cbic.201100793","article-title":"Identification of hydrophobic tags for the degradation of stabilized proteins","volume":"13","author":"Tae","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118617_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115741","article-title":"Hydrophobic tag-based protein degradation: development, opportunity and challenge","volume":"260","author":"He","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118617_bib52","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1258\/ebm.2009.009250","article-title":"Proposal for a role of the Hsp90\/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage","volume":"235","author":"Pratt","year":"2010","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118617_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052099","article-title":"The type II Hsp40 sis1 cooperates with Hsp70 and the E3 ligase Ubr1 to promote degradation of terminally misfolded cytosolic protein","volume":"8","author":"Summers","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.ejmech.2026.118617_bib54","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s00018-006-6192-6","article-title":"The diversity of the DnaJ\/Hsp40 family, the crucial partners for Hsp70 chaperones","volume":"63","author":"Qiu","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118617_bib55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4155\/fmc-2016-0193","article-title":"Progress in the medicinal chemistry of silicon: c\/si exchange and beyond","volume":"9","author":"Fujii","year":"2017","journal-title":"Future Med. Chem."},{"issue":"70","key":"10.1016\/j.ejmech.2026.118617_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scirobotics.abo4160","article-title":"Gastrointestinal tract drug delivery using algae motors embedded in a degradable capsule","volume":"7","author":"Zhang","year":"2022","journal-title":"Sci. Robot."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:11:18Z","timestamp":1777529478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":56,"alternative-id":["S0223523426000620"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118617","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118617"}}